Drug Profile

Pneumococcal polysaccharide vaccine 23-valent - Beijing Minhai Biotechnology

Alternative Names: 23-valent pneumococcal polysaccharide vaccine - Beijing Minhai Biotechnology

Latest Information Update: 05 Sep 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Beijing Minhai Biotechnology
Developer Beijing Minhai Biotechnology; Jiangsu Provincial Center for Disease Control and Prevention
Class Pneumococcal vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

31 Aug 2022 Pneumococcal polysaccharide vaccine 23-valent licensed to PharmaWealth in Phillipines
21 Mar 2022 Beijing Minhai Biotechnology and PharmaWealth entered in a clinical collaboration agreement
13 Aug 2019 Launched for Pneumococcal infections (In adolescents, In children, In the elderly, Prevention, In adults) in China (IM)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com